AbbVie's epcoritamab combo meets primary endpoint in lymphoma trial

June 29, 2026 4:15 PM

AbbVie (NYSE: ABBV) announced topline results from the Phase 3 EPCORE DLBCL-4 trial showing that epcoritamab combined with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found